03:48

Preliminary results from Phase I study of CD123 CAR-T therapy in pediatric R/R AML

02:47

KarMMa-3 results: ide-cel vs standard regimens in triple-class exposed multiple myeloma

03:02

Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL

03:19

Safety and efficacy of LV20.19 CAR-T therapy in Richter's transformation and R/R MCL

03:52

Outcomes of children and young adults with B-ALL following tisa-cel reinfusion

05:15

CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT

01:13

An insight into novel third-generation TLR2 co-stimulatory CAR-T cells

02:15

Challenges with CAR-T therapy in AML & insights into IF-BETTER-gated CAR-T cells

01:26

Rapid CAR-T manufacturing and challenges in this space

02:17

The importance of managing hematologic toxicity associated with CAR-T therapy

02:21

Exploring the potential role of CD7-targeting CAR-T cells in T-ALL

00:55

Multivalent gamma-delta T-cells: promising agents for the treatment of cancers

08:25

CAR-T therapy in acute and chronic leukemias: current applications and future outlooks

01:05

Novel CAR-T constructs emerging for patients with multiple myeloma who experience loss of BCMA

05:36

Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy

01:00

Trials evaluating the efficacy of CD20 CAR-T cell therapy in WM and CNS lymphoma

02:45

Phase I study of CC-98633 in R/R multiple myeloma

03:59

Results from the first-in-human trial of huCART19-IL18 in patients with R/R NHL and CLL

02:08

Results from a Phase I trial of rapidly manufactured Prgn-3006 Ultracar-T in R/R AML

02:52

The safety and efficacy of UCART123v1.2 in R/R AML: results from AMELI-01

01:23

CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL

01:59

Developing gene therapies for GJB2 gene related hearing loss

02:05

Novel gene therapy solutions for Usher syndrome type I

02:51

Treating otoferlin deficiency with gene therapy

02:41

Developing a therapeutic cancer vaccine for patients with NSCLC

01:34

Assessing PDC*mel, dendritic cell-based vaccine in melanoma

01:43

Plasmacytoid dendritic cell-based cancer vaccines

02:56

SCUlpTOR: CYP-004 in osteoarthritis

03:00

CYP-001 in adults with steroid-resistant GvHD

03:10

Utilizing flow cytometry in CAR T-cell research

01:28

Implementing automation technology in the CGT space

02:08

Streamlining cell therapy manufacturing with CliniMACS Prodigy

01:04

Applications of stem cell gene therapy beyond genetic diseases

02:24

CAR T-cell therapy for neuroblastoma

01:13

PiggyBac Transposon-generated CAR T-cells in solid tumors

02:34

Generating iSPC-derived MSCs with the Cymerus™ Platform

03:00

Addressing challenges in using MSCs in cell therapies

01:01

The future of omentum-based autologous tissue engineering

01:36

Meeting the growing demand for gene therapy manufacturing

02:12

Innovations in treating rare diseases with gene therapies

01:38

Overcoming manufacturing issues in gene therapies for rare diseases

01:35

Restoring cardiac tissue with omentum-based hydrogel implants

02:36

Autologous tissue-engineered solutions for spinal cord injuries

01:27

Direct detection and isolation of CAR cells from patient samples

04:06

Optimizing the upscaling and outscaling of CAR T-cell therapies

01:22

Engineering NK cell-based cancer treatments

02:30

Moving CAR T-cell therapies to earlier lines of therapy in multiple myeloma

05:56

Targeting neoantigens in multiple myeloma with CAR T-cell

02:59

Photoporation with polydopamine nanosensitizers for mRNA delivery to T cells

02:37

The benefits of PiggyBac transposon-mediated CAR-T cell technology

01:23

Enhancing the long-term functionality of CAR-T cells in solid tumors

05:33

Improving immune-imaging tools to assess cancer immunotherapies

04:27

Developing individualized cancer therapies with neoantigen-specific TCRs

02:20

Overcoming barriers in treating liquid tumors with T-cell therapies

03:22

Assessing immunotherapies with a novel tumor model using humanized mice

03:25

An overview of mouse models to study cell therapies for cancer

05:36

Harnessing lipid-specific TCRs to target CD1c-expressing leukemia

03:05

The anti-leukemic potential of CD1c-restricted T cells

01:33

Improving the efficiency of cancer vaccines with adoptive T cell therapy approaches

03:52

Addressing immunogenic barriers facing CRISPR-Cas9-based therapies